Morning Briefing
Summaries of health policy coverage from major news organizations
Pharmacy Benefit Managers Will Soon Be Required To Disclose Pricing, Payment Data
The Wall Street Journal: Drug Middlemen Will Soon Have To Share Details On How They Are Paid
The Trump administration will require the companies that manage hundreds of billions of dollars of drug spending to disclose details on how they get paid. Under a new regulation from the Labor Department expected to be released Thursday, pharmacy-benefit managers will have to provide their employer clients with granular information about the prices they pay for pharmaceuticals, as well as payments they receive from drugmakers, according to people with knowledge of the matter. (Wilde Mathews and Essley Whyte, 10/28)
More pharmaceutical news —
Stat: GAO Should Study If TrumpRx Saved People Money, Lawmaker Says
A House lawmaker asked the Government Accountability Office to review whether the TrumpRx platform has saved Americans any money. (Silverman, 10/28)
Undark: The FDA Wants To Pull Its Approval Of A Drug. It’s Not So Easy
In May 2021, the U.S. Food and Drug Administration released a lengthy briefing document on an experimental medication for a rare autoimmune form of vasculitis that often damages the kidneys and lungs. The agency was on the fence about whether to approve the treatment, and it wanted an independent advisory committee to weigh in. Among the questions at hand: Was the drug meaningfully better than existing therapies? (Talpos, 10/28)
Stat: Lilly's 'Triple-G' Drug Bests Ozempic In Head-To-Head Study
Eli Lilly on Wednesday said that its investigational drug was more effective at lowering blood sugar and cutting weight than Novo Nordisk’s Ozempic in a large diabetes study, further boosting the competitive profile of its medicine. (Chen, 10/28)
The Wall Street Journal: Here’s Why Moderna’s CEO Isn’t Fazed By Its Cancer-Vaccine Selloff
Moderna Chief Executive Stéphane Bancel thinks investors are wrong about the company’s cancer vaccine. Moderna’s stock fell sharply over the past few days after data emerged about its cancer vaccine that investors found disappointing, though researchers called it breakthrough. (Martinez, 10/28)
KFF Health News: Listen To The Latest ‘KFF Health News Minute’
Arielle Zionts reads the week’s news: Prescription drugs can be lifesavers, but taking many different meds can be risky. Plus, people shopping for Obamacare plans for next year may see some changes. (10/29)
